The Taiwan Food and Drug Administration (FDA) has granted emergency use authorization to Covid-19 vaccine Novavax, on June 17, 2022. The expert committee decided to go ahead with the authorization for the protein-based vaccine after doing an overall assessment and keeping in mind the requirements of public health.
Novavax will be available in Taiwan for adults over the age of 18. The FDA has also mentioned in a statement that the vaccine was safe and effective, and was essential to fight the surge of new variants.
In April 2022, Taiwan’s Health and Welfare Minister, Chen Shih-Chung had announced that Taiwan would receive close to 2 million doses of Novavax to strengthen their vaccination program. They will receive these vaccines through the global vaccine sharing initiative COVAX.
According to data released by Central Epidemic Command Center (CECC), 91.12 percent of Taiwan’s 23 million population have received one dose of a covid-19 vaccine. While 82.53 have received two doses. Taiwan has also begun administering the third booster shots in December 2021.